Home / Isis Launches Phase I/II Clinical Trial of ISIS-DMPKrx to Treat DM1

Isis Launches Phase I/II Clinical Trial of ISIS-DMPKrx to Treat DM1

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has initiated a Phase I/II trial for ISIS-DMPKrx in patients affected by myotonic dystrophy type 1 (DM1).

This study is designed to evaluate the safety and tolerability of multiple doses of an investigational compound, ISIS-DMPKrx, in adult patients with DM1. ISIS-DMPKrx is designed to reduce the production of toxic dystrophia myotonic-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of DM1.

Questions? Visit the MDF Clinical Trials Resource Center. Up-to-date information regarding trial sites, recruitment and trial site contact information is posted on www.clinicaltrials.gov.

[Update: Results from the Phase I/II Trial study were announced on January 5, 2017: Ionis Pharmaceuticals Reports DMPKRx Phase 1/2 Trial Results. Ionis Pharmaceuticals and Biogen also released a letter to the DM community in January 2017.]

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.